Autonomix Medical, Inc. is a development stage medical device development company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. The company is headquartered in The Woodlands, Texas and currently employs 8 full-time employees. The company went IPO on 2024-01-29. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity. The company is developing its technology for pancreatic cancer and pancreatitis, conditions that can cause debilitating pain and need an effective solution. Its technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Its development efforts are divided into two parts: diagnostic sensing and therapeutic radiofrequency ablation. The firm is developing Autonomix system, which is primarily catheter-based, meaning that its sensing equipment is delivered to its targeted location via a lumen within the body.
最新の財務諸表(Form-10K)によると、Autonomix Medical Incの総資産は$0で、純損失は$0です。
AMIXの主要な財務比率は何ですか?
Autonomix Medical Incの流動比率は0、純利益率は0、1株当たり売上高は$0です。
Autonomix Medical Incの収益はセグメントまたは地域別にどのように分けられていますか?
Autonomix Medical Inc の最大収益セグメントは Growth Direct Systems, Proprietary Consumables, Laboratory Information Management System Connection Software で、最新の利益発表における収益は 18,728,000 です。地域別に見ると、United States が Autonomix Medical Inc の主要市場であり、収益は 10,639,000 です。